Viatris Inc
NASDAQ:VTRS
Viatris Inc
Cash from Operating Activities
Viatris Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Viatris Inc
NASDAQ:VTRS
|
Cash from Operating Activities
$2.8B
|
CAGR 3-Years
31%
|
CAGR 5-Years
4%
|
CAGR 10-Years
10%
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
See Also
What is Viatris Inc's Cash from Operating Activities?
Cash from Operating Activities
2.8B
USD
Based on the financial report for Dec 31, 2023, Viatris Inc's Cash from Operating Activities amounts to 2.8B USD.
What is Viatris Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
10%
Over the last year, the Cash from Operating Activities growth was -5%. The average annual Cash from Operating Activities growth rates for Viatris Inc have been 31% over the past three years , 4% over the past five years , and 10% over the past ten years .